Samedan Ltd Pharmaceutical Publishers


Advanced search

Publications European Pharmaceutical Contractor European Biopharmaceutical Review International Clinical Trials Pharmaceutical Manufacturing and Packing Sourcer Innovations in Pharmaceutical Technology Subscribe Online Conferences White Papers Samedan app Pharmaceutical Directory Industry Events Calendar News and Press Releases Employment Opportunities Advertising with us Contact Us

home > pmps > Autumn 2008

PUBLICATIONS

Pharmaceutical Manufacturing and Packing Sourcer

Autumn 2008

At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. PMPS provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of PMPS.

Text

PDF

Manufacturing

Brian Dougherty of SCM Pharma Ltd suggests that it is time to seek out new ways to capitalise on innovation in the clinical manufacturing sector

Felix Nink at Bosch argues that automation and modular design are radically changing how pharmaceutical processing looks at containment

Benoоt Verjans of Aseptic Tech introduces closed vial technology: a new methodology for aseptic filling of injectable drugs

Kevin Menard at PerkinElmer Life and Analytical Sciences cites hyphenated techniques as the next generation in laboratory advancements for the pharmaceutical industry

Getting a potential new drug or product from the research and development stage into use has to be the key commercial consideration for pharmaceutical companies. Mark Perry from Siemens Automation and Drives explains how embracing manufacturing execution systems (MES) can have a real impact in an industry when every day counts towards financial success

Drug Delivery

Dr Renaud Janssen at Helvoet Pharma examines the use of silicon in the manufacture of pre-filled syringes, and details its importance in the production of a safe, high-quality product

François Dessus and Flore Demay at Stelmi discuss how to ensure the highest degree of assurance in the production of rubber stoppers sterilised by gamma irradiation

Cedric Marmonier at Rovipharm traces the development of liquid drug administration from the spoon to the syringe, and examines possible future development

Paul Kippax of Malvern Instruments and David Morton of Monash University assess the benefits of using dry powder inhalers in order to optimise the delivery of a wide range of medicinal drugs

Ed Wynn at ANSYS analyses the impact of computational fluid dynamics on pulmonary drug delivery

Formulations, Ingredients and Excipients

Kevin Maynard at Imprint Pharmaceuticals and Victor Breedveld from the Georgia Institute of Technology discuss particle tracking microrheology

Partnerships between pharma and excipient manufacturers can extend drug patents through novel functionalities and formulations; Hans Huttinga at Sheffield Pharma Ingredients investigates

IT and Logistics

Leigh Jordan at Cognex UK Ltd identifies machine vision and coding as essential ingredients of an efficient traceability strategy

Chris Stumpf and Phil Kilby at Waters discuss lean process improvements for the GMP laboratory

PACKING, PACKAGING & ANTI-COUNTERFEITING

Benjamin Kepp of Bischof + Klein GmbH discusses how flexible packaging can solve contamination problems across the whole drug development process

John Gill at the Royal National Institute for the Blind discusses what can be done by pharmaceutical packagers to help blind and partially sighted people

Gerhard Breu at Körber Medipak explains how the bar in patient compliance can be raised through box wallet packaging

With pharmaceutical labelling becoming increasingly regulated, manufacturers and packaging companies are looking for a simple and cost-effective solution. Mark Beauchamp at Citizen Systems Europe explains that the latest generation of label printing technology can meet both requirements

Paul Stiff at Farnham Castle International Briefing Centre examines the inherent difficulties in recognising international commercial needs in packaging and manufacturing

COOL CHAIN

Geraint Thomas at Laminar Medica explains how the latest temperature-controlled packaging technology is helping pharmaceutical companies meet the growing challenge of shipping temperature-sensitive products

Chris Fore at Envirotainer presents strategies to meet transport service provider obligations as defined in Parental Drug Association Technical Report Number 39

In the current financial climate, making the correct choice when selecting chillers and air conditioning systems is more important than ever; Steve Warnock of the Coolmation Group explains why the sector should consider Turbocor compressor chillers when reviewing climate control

Tony Wright at Exelsius Cold Chain Management Consultancy examines cold chain management, and tells us it is key to securing both patient safety and the quality of pharmaceutical products

Tim Jennings of Emball’iso SA talks to PMPS about the expanding cold chain sector of the pharmaceutical industry

Published quarterly in
February, May,
August, and November

News and Press Releases

Survey Finds Industry Taking Action to Address Challenges from Rapid Move to Decentralized Trials Amid COVID-19

Sponsors and contract research organizations (CROs) are accelerating digital transformation to advance toward patient-centric, paperless, and decentralized trials, according to the Digital Clinical Trials Survey Report conducted by Veeva Systems (NYSE: VEEV).
More info >>

All releases >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

All white papers >>